Valuation: GlaxoSmithKline Pakistan Limited

Market Cap 107B 388M 348M 318M 291M 547M 36.5B 565M 3.84B 1.53B 19.47B 1.46B 1.43B 61.48B P/E 2026 *
10.2x
P/E 2027 * 8.5x
Enterprise Value 107B 388M 348M 318M 291M 547M 36.5B 565M 3.84B 1.53B 19.47B 1.46B 1.43B 61.48B EV / Sales 2026 *
1.56x
EV / Sales 2027 * 1.44x
Free-Float
16.89%
Yield 2026 *
5.35%
Yield 2027 * 5.97%
Oct. 29 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 CI
Sep. 03 GlaxoSmithKline Pakistan Limited Announces Appointment of Muhammad Yousuf Vohra as Chief Financial Officer, Effective October 15, 2026 CI
Sep. 03 GlaxoSmithKline Pakistan Limited Announces Appointment of Muhammad Yousuf Vohra as Finance Director, Effective October 15, 2026 CI
Aug. 28 GlaxoSmithKline Pakistan Limited Announces Appointment of Muhammad Masood Ahmed Khan to Executive Director, Effective August 28, 2026 CI
Aug. 25 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
Aug. 25 GlaxoSmithKline Pakistan Limited Interim Cash Dividend for the Half Year Ended June 30, 2026, Payable on September 11, 2026 CI
Aug. 02 GlaxoSmithKline Pakistan Limited Appoints Umair Majeed as Interim/Acting Chief Financial Officer, Effective from July 30, 2026 CI
Aug. 02 GlaxoSmithKline Pakistan Limited Announces Appointment of Hasham Ali Baber as Non-Executive Director, Effective July 30, 2026 CI
Jun. 08 GlaxoSmithKline Pakistan Limited Announces Resignation of Hasham Baber as Chief Financial Officer, Effective June 30, 2026 CI
Jun. 08 GlaxoSmithKline Pakistan Limited Announces Resignation of Hasham Baber as Executive Director of the Board of Directors, Effective June 30, 2026 CI
May. 31 GlaxoSmithKline Pakistan Limited Announces Resignation of Ana Paula De Freitas Passos as Non-Executive Director, Effective May 31, 2026 CI
Apr. 30 GlaxoSmithkline Pakistan Limited Approves Final Cash Dividend for the Year Ended 31 December, 2025 CI
Apr. 30 GlaxoSmithkline Pakistan Limited Approves Board Elections, Effective May 25, 2026 CI
1 day-0.79%
1 week+3.47%
Current month+5.61%
1 month+9.58%
3 months-4.48%
6 months-4.10%
Current year-13.46%
1 week 316.06
Extreme 316.06
342
1 month 305
Extreme 305
342
Current year 293.09
Extreme 293.09
459.27
1 year 293.09
Extreme 293.09
459.27
3 years 75.01
Extreme 75.01
481
5 years 68
Extreme 68
481
10 years 68
Extreme 68
481
Manager TitleAgeSince
Chief Executive Officer - 2020-02-29
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member - 2011-05-06
Director/Board Member - 2018-12-04
Director/Board Member 72 2020-04-01
Change 5-day change 1-year change 3-year change Capi.($)
-0.79%+3.47%-13.69%+316.74% 391M
-0.79%-1.43%+46.25%+138.46% 1,216B
+1.43%+0.37%+48.51%+82.52% 656B
+1.07%+0.18%+34.39%+105.99% 509B
-0.36%-2.84%+47.23%+64.51% 384B
-0.14%+0.27%+73.87%+41.93% 362B
-0.78%+0.59%+31.01%+59.68% 311B
-0.80%+6.73%+11.89%+35.64% 293B
+0.03%-0.07%+43.94%+70.61% 249B
-0.41%+0.77%+36.15%+104.55% 208B
Average -0.15%+1.15%+35.95%+102.06% 418.82B
Weighted average by Cap. -0.05%+0.04%+43.46%+91.88%

Financials

2026 *2027 *
Net sales 68.81B 249M 223M 204M 186M 351M 23.38B 362M 2.46B 980M 12.47B 933M 913M 39.38B 74.58B 270M 242M 221M 202M 380M 25.34B 392M 2.66B 1.06B 13.52B 1.01B 990M 42.68B
Net income 10.49B 37.91M 34M 31.08M 28.37M 53.45M 3.56B 55.13M 375M 149M 1.9B 142M 139M 6B 12.42B 44.89M 40.26M 36.8M 33.59M 63.28M 4.22B 65.28M 444M 177M 2.25B 168M 165M 7.11B
Net Debt - -
Projected Income Statement - Annual - GlaxoSmithKline Pakistan Limited
Logo GlaxoSmithKline Pakistan Limited
GlaxoSmithKline Pakistan Limited is a Pakistan-based global biopharma company. The Company is engaged in the manufacturing and marketing of research-based specialties and pharmaceutical products. It caters to therapy areas, such as anti-infectives, dermatology, respiratory, analgesics, urology, and vaccines. Its pharmaceutical brands include Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Calpol and Ventolin. Its portfolio has three product areas: vaccines, specialty, and general medicines. Its Amoxil branded products are an antibiotic indicated for the treatment of upper respiratory tract infections and helicobacter pylori. Its Vates portfolio comprises brands, such as Dermovate, Clobevate, Cutivate, and Betnovate. Its Vates portfolio addresses to a broad category of steroid responsive dermatoses indications, contact, and other kinds of dermatitis. Its Calpol branded products are used for treatment of mild to moderate fever and pain.
Employees
1,606
Date Price Change Volume
26-11-06 PKR 337.31 -0.79% 183,864
26-11-05 PKR 340.01 +3.19% 526,559
26-11-04 PKR 329.51 +3.73% 235,194
26-11-03 PKR 317.65 -0.10% 18,770
26-11-02 PKR 317.97 -0.44% 41,430
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
337.31PKR
Average target price
510.00PKR
Spread / Average Target
+51.20%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - GlaxoSmithKline Pakistan Limited
  1. Stock Market
  2. Stocks
  3. GLAXO Stock